CONTEXT: MR and ultrasound can noninvasively assess the relative blood volume (rBV) within a tumor to possibly aid diagnosis and treatment planning. The relationships among rBV, blood vessel density, and tumor size had not been reported, however, until investigators at Toronto's Sunnybrook and Women's College Health Sciences Centre presented study results at the ISMRM meeting in May.
RESULTS: Contrast-enhanced MR, vascular ultrasound, and micro-CT were performed on New Zealand white rabbits harboring VX2 tumors with a median size of 9 cm3. Blood volume fraction (BVF) was calculated by comparing MR data collected from the tumor site before and after the injection of Clariscan, an intravascular superparamagnetic iron oxide contrast agent. Blood vessel density was also assessed by 3D MR. Ultrasound evaluation of tumor rBV involved injection of an intravascular microbubble contrast. Principal investigator Dr. Xiuling Qi compared contrast signals from the tumor, adjacent muscle, and, when possible, a major vessel. Micro-CT studies were used to assess microcirculation in the tumor tissue rim. The results indicate that regional blood volume in the tumor rim decreases as tumor size increases. RBV, measured with contrast-enhanced MR and ultrasound, was qualitatively consistent with blood vessel density. Micro-CT and 3D MR results suggest an inverse relationshi!p between tumor vessel density in the rim and tumor size, meaning that blood vessel density decreases as tumor size increases.
IMAGES: Enhanced 3D MR image of a 15-cm3 tumor (top) demonstrates less vessel density in its peripheral regions than a 9-cm3 tumor (bottom).
IMPLICATIONS: The observation that small tumors have increased blood vessel density might reflect rapid growth and the relative absence of necrosis. Clinically, the results suggest that these molecular imaging approaches have a role in optimizing the timing of cancer therapies designed to inhibit development of tumor vasculature.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.